Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for AnaptysBio, Inc. (ANAB : NSDQ)
 
 • Company Description   
AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California.

Number of Employees: 104

 
 • Price / Volume Information   
Yesterday's Closing Price: $54.15 Daily Weekly Monthly
20 Day Moving Average: 861,614 shares
Shares Outstanding: 29.61 (millions)
Market Capitalization: $1,603.27 (millions)
Beta: 0.68
52 Week High: $72.36
52 Week Low: $11.58
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -9.27% -9.93%
12 Week -17.62% -19.87%
Year To Date 11.70% 4.66%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
10770 WATERIDGE CIRCLE SUITE 210
-
SAN DIEGO,CA 92121
USA		 ph: 858-362-6295
fax: -		 investors@anaptysbio.com http://www.anaptysbio.com
 
 • General Corporate Information   
Officers
Daniel Faga - President; Chief Executive Officer and Director
Dennis Mulroy - Chief Financial Officer
Dennis Fenton - Director
Rita Jain - Director
Magda Marquet - Director

Peer Information
AnaptysBio, Inc. (CORR.)
AnaptysBio, Inc. (RSPI)
AnaptysBio, Inc. (CGXP)
AnaptysBio, Inc. (BGEN)
AnaptysBio, Inc. (GTBP)
AnaptysBio, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 032724106
SIC: 2834
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 03/01/26
Next Expected EPS Date: 08/05/26
Share - Related Items
Shares Outstanding: 29.61
Most Recent Split Date: (:1)
Beta: 0.68
Market Capitalization: $1,603.27 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $0.11 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $-1.35 Payout Ratio:
Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: 04/20/2026 - $22.51
Next EPS Report Date: 08/05/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -
Price Ratios
Price/Book: 123.62
Price/Cash Flow: -
Price / Sales: 6.90
EPS Growth
vs. Year Ago Period: -43.75%
vs. Previous Quarter: -216.46%
Sales Growth
vs. Year Ago Period: -7.98%
vs. Previous Quarter: -76.39%
ROE
06/30/26 - -
03/31/26 - -
12/31/25 - -
ROA
06/30/26 - -
03/31/26 - -7.75
12/31/25 - -3.59
Current Ratio
06/30/26 - -
03/31/26 - 7.58
12/31/25 - 9.07
Quick Ratio
06/30/26 - -
03/31/26 - 7.58
12/31/25 - 9.07
Operating Margin
06/30/26 - -
03/31/26 - -11.53
12/31/25 - -5.64
Net Margin
06/30/26 - -
03/31/26 - -11.53
12/31/25 - -5.64
Pre-Tax Margin
06/30/26 - -
03/31/26 - -11.46
12/31/25 - -5.57
Book Value
06/30/26 - -
03/31/26 - 0.44
12/31/25 - 1.34
Inventory Turnover
06/30/26 - -
03/31/26 - -
12/31/25 - -
Debt-to-Equity
06/30/26 - -
03/31/26 - 0.00
12/31/25 - 0.00
Debt-to-Capital
06/30/26 - -
03/31/26 - 0.00
12/31/25 - 0.00
 

Powered by Zacks Investment Research ©